Connection

WILLEM OVERWIJK to Vaccines, Synthetic

This is a "connection" page, showing publications WILLEM OVERWIJK has written about Vaccines, Synthetic.
Connection Strength

0.194
  1. B16 as a mouse model for human melanoma. Curr Protoc Immunol. 2001 May; Chapter 20:Unit 20.1.
    View in: PubMed
    Score: 0.043
  2. Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res. 2000 Jan 15; 60(2):253-8.
    View in: PubMed
    Score: 0.039
  3. Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. Methods. 1997 Jun; 12(2):117-23.
    View in: PubMed
    Score: 0.032
  4. Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A. 1997 Apr 01; 94(7):3183-8.
    View in: PubMed
    Score: 0.032
  5. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol. 1996; 397:7-13.
    View in: PubMed
    Score: 0.029
  6. Immunization against endogenous retroviral tumor-associated antigens. Cancer Res. 2001 Nov 01; 61(21):7920-4.
    View in: PubMed
    Score: 0.011
  7. Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. Vaccine. 1997 Mar; 15(4):387-94.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.